3.4.21.B42	adrenal gland	expression revealed by immunohistochemistry	667873	
3.4.21.B42	apocrine gland	expression revealed by immunohistochemistry	667873	
3.4.21.B42	bile duct epithelium	expression revealed by immunohistochemistry	667873	
3.4.21.B42	BPH cell	-	718165	
3.4.21.B42	brain	-	709810	
3.4.21.B42	brain	brain-type isozyme, secreted into the medium	647365	
3.4.21.B42	breast cancer cell line	KLK11 is upregulated by estrogens, dexamethasone, androgens and progestins in breast cancer cell lines	691150	
3.4.21.B42	breast carcinoma cell	-	680247	
3.4.21.B42	breast epithelium	expression revealed by immunohistochemistry	667873	
3.4.21.B42	bronchial epithelium	expression revealed by immunohistochemistry	667873	
3.4.21.B42	bronchioalveolar carcinoma cell	decreased mRNA level compared to nonmalignant lung tissue	668302	
3.4.21.B42	cerebral cortex	expression revealed by immunohistochemistry	667873	
3.4.21.B42	cervical cancer cell line	KLK11 is upregulated by estrogens in cervical cancer cell lines but downregulated by dexamethasone	691150	
3.4.21.B42	cervical epithelium	expression revealed by immunohistochemistry	667873	
3.4.21.B42	choroid plexus	expression revealed by immunohistochemistry	667873	
3.4.21.B42	eccrine sweat gland	expression revealed by immunohistochemistry	667873	
3.4.21.B42	ejaculatory duct epithelium	expression revealed by immunohistochemistry	667873	
3.4.21.B42	endometrium	-	682813	
3.4.21.B42	epithelium	prostate	647365	
3.4.21.B42	esophagus	expression revealed by immunohistochemistry	667873	
3.4.21.B42	gall bladder epithelium	expression revealed by immunohistochemistry	667873	
3.4.21.B42	ganglion	expression revealed by immunohistochemistry	667873	
3.4.21.B42	gastric cancer cell	-	718041	
3.4.21.B42	gastric mucosa	-	718041	
3.4.21.B42	glial cell	expression revealed by immunohistochemistry	667873	
3.4.21.B42	heart	brain-type isozyme	647365	
3.4.21.B42	hippocampus	especially expressed in pyramidal neurons	647365	
3.4.21.B42	hippocampus	isozyme 1	679747	
3.4.21.B42	KP-N-YN cell	-	679747	
3.4.21.B42	Langerhans cell	expression revealed by immunohistochemistry	667873	
3.4.21.B42	Leydig cell	expression revealed by immunohistochemistry	667873	
3.4.21.B42	lung	gene expression,no significant difference to cancerous tissue	667878	
3.4.21.B42	lung	prostate-type isozyme	647365	
3.4.21.B42	lung adenocarcinoma cell	decreased mRNA level compared to nonmalignant lung tissue	668302	
3.4.21.B42	lung cancer cell	gene expression, no significant difference to non-cancerous tissue	667878	
3.4.21.B42	mammary gland	-	680247	
3.4.21.B42	MCF-7 cell	-	680247	
3.4.21.B42	MDA-MB-231 cell	-	680247	
3.4.21.B42	MDA-MB-468 cell	-	680247	
3.4.21.B42	nerve	expression revealed by immunohistochemistry	667873	
3.4.21.B42	neuroblastoma cell line	-	679747	
3.4.21.B42	neuron	expression revealed by immunohistochemistry	667873	
3.4.21.B42	neuron	pyramidal, hippocampus	647365	
3.4.21.B42	non-small cell lung cancer cell	patients with a high enzyme activity have a longer longer overall survival and progression free survival, expression analysis in 138 cancer samples and 40 healthy controls	732964	
3.4.21.B42	ovary	expression revealed by immunohistochemistry	667873	
3.4.21.B42	ovary cancer cell	gene expression	668270	
3.4.21.B42	parathyroid gland	expression revealed by immunohistochemistry	667873	
3.4.21.B42	pericardium	expression revealed by immunohistochemistry	667873	
3.4.21.B42	peritoneum	expression revealed by immunohistochemistry	667873	
3.4.21.B42	pleura	expression revealed by immunohistochemistry	667873	
3.4.21.B42	prostate	especially expressed in secretory epithelial cells	647365	
3.4.21.B42	prostate	prostate-type isozyme, secreted into the medium	647365	
3.4.21.B42	prostate cancer cell	-	678527, 709810, 718165	
3.4.21.B42	prostate cancer cell	higher levels of kallikrein 11 compared to non-cancerous cells	667879	
3.4.21.B42	prostate cancer cell	increased mRNA level compared to non-cancerous cells	668294	
3.4.21.B42	prostate cancer cell line	-	718165	
3.4.21.B42	prostate gland	-	718165	
3.4.21.B42	prostate gland	isozyme 2	679747	
3.4.21.B42	rectal carcinoma cell	overexpression of human kallikrein 11 is associated with poor prognosis in patients with low rectal carcinoma	693983	
3.4.21.B42	respiratory epithelium	expression revealed by immunohistochemistry	667873	
3.4.21.B42	salivary gland	expression revealed by immunohistochemistry	667873	
3.4.21.B42	seminal plasma	-	668284	
3.4.21.B42	seminal vesicle	expression revealed by immunohistochemistry	667873	
3.4.21.B42	serum	-	679272	
3.4.21.B42	spermatheca	expression revealed by immunohistochemistry	667873	
3.4.21.B42	submucosa	expression revealed by immunohistochemistry	667873	
3.4.21.B42	T-47D cell	-	680247	
3.4.21.B42	thymus	expression revealed by immunohistochemistry	667873	
3.4.21.B42	tonsil	expression revealed by immunohistochemistry	667873	
3.4.21.B42	urethra	expression revealed by immunohistochemistry	667873	
3.4.21.B42	urothelium	expression revealed by immunohistochemistry	667873